PT - JOURNAL ARTICLE AU - Leslie R. Harrold AU - Bradley S. Stolshek AU - Sabrina Rebello AU - David H. Collier AU - Alex Mutebi AU - Sally W. Wade AU - Wendi Malley AU - Jeffrey D. Greenberg AU - Carol J. Etzel TI - Rebound in Measures of Disease Activity and Symptoms in Corrona Registry Patients with Psoriatic Arthritis Who Discontinue Tumor Necrosis Factor Inhibitor Therapy after Achieving Low Disease Activity AID - 10.3899/jrheum.161567 DP - 2018 Jan 01 TA - The Journal of Rheumatology PG - 78--82 VI - 45 IP - 1 4099 - http://www.jrheum.org/content/45/1/78.short 4100 - http://www.jrheum.org/content/45/1/78.full SO - J Rheumatol2018 Jan 01; 45 AB - Objective. Rebound may occur in patients with psoriatic arthritis (PsA) who discontinue TNF inhibitor (TNFi) therapy in low disease activity (LDA).Methods. Using physician and patient reports, we quantified rebound following TNFi discontinuation [defined as Clinical Disease Activity Index (CDAI) score > 10 or TNFi restart] and time to rebound in adults with PsA in LDA (CDAI score ≤ 10) at TNFi discontinuation.Results. Rebound occurred in 73% (69/94) of patients soon after discontinuation (median time to rebound 8.0 mos, 95% CI 6.0–12.0).Conclusion. Rebound occurred frequently in patients with PsA after TNFi discontinuation. TNFi discontinuation after achieving LDA should be carefully considered.